42
0 mo
1 mo
3 mo
SIHD
6 mo
PCI
12 mo
>6 mo of
DAPT may be
reasonable
(2b)
>I mo of
DAPT may be
reasonable
(2b)
BMS
DES
Discontinuation
of P2Y12 after
3 mo may be
reasonable
(2b)
High risk
of bleeding
or overt
bleeding
on DAPT
Discontinuation of aspirin after 1–3 mo
with continued P2Y12 monotherapy
(2a)
At least
1 mo of
aspirin +
clopidogrel
(1)
No high risk of bleeding and no
significant overt bleeding on DAPT
At least 6
mo aspirin +
clopidogrel
(1)
Figure 7. Use of DAPT for Patients After PCI
Colors correspond to Class of Recommendations and Level of Evidence tables on
pages 48–49.
Treatment
